“I think this is an area that needs to be really personalized to each clinical practice,” says Alicia K. Morgans, MD, MPH.
In this video, Alicia K. Morgans, MD, MPH, discusses the practices she implements regarding germline and somatic testing in patients with advanced prostate cancer. These ideas were focused on in her presentation, “Advanced disease: incorporating molecular markers and genomic studies into therapy,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Morgans is a genitourinary medical oncologist and medical director of the Survivorship Program at the Dana-Farber Cancer Institute in Boston, Massachusetts.
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.